Table 2.
The % Change in Prescription Costs to Switch a Drug Class from pMDI to All DPI at the Average Sales Price per Dose of the DPI
| USA | Germany | UK | Japan | China | France | Canada | Spain | Italy | Brazil | India | Australia | Poland | Russia | Puerto Rico | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SABA | 114% | 147% | 290% | 132% | 213% | 171% | 566% | 304% | 277% | X | 102% | 170% | 290% | X | 105% |
| SAMA | X | X | X | X | X | X | X | X | N/A | X | 101% | X | X | X | X |
| SABA/SAMA | o | 205% | N/A | N/A | X | 596% | o | N/A | X | X | 121% | N/A | X | X | o |
| ICS | 93% | 81% | 121% | 90% | 100% | 101% | 60% | 99% | 107% | 104% | 101% | 64% | 80% | 100% | 100% |
| LABA | o | 92% | 92% | o | o | 100% | o | 107% | 99% | o | 102% | o | 95% | 95% | o |
| LAMA | o | o | o | 100% | o | o | o | o | o | o | 148% | o | o | o | o |
| LABA/ICS | 111% | 91% | 85% | 102% | 100% | 97% | 88% | 92% | 100% | 100% | 102% | 89% | 93% | 99% | 117% |
| LABA/LAMA | 105% | o | o | o | o | o | o | o | o | o | 147% | o | o | o | 104% |
| Triple | 100% | 155% | 148% | o | N/A | 142% | o | 182% | 161% | N/A | 152% | o | X | N/A | o |
| TOTAL | 106% | 102% | 107% | 101% | 113% | 107% | 110% | 104% | 106% | 101% | 108% | 103% | 96% | 99% | 107% |
| Total excl. relievers | 105% | 97% | 95% | 100% | 100% | 99% | 85% | 97% | 106% | 101% | 106% | 92% | 91% | 99% | 107% |
| Market size $M | $24,774 | $1394 | $1,293 | $1,280 | $1,220 | $894 | $846 | $751 | $685 | $335 | $315 | $314 | $271 | $219 | $201 |
Notes: Drug class abbreviations (SABA, SAMA etc) as defined in the text: Red text indicates a greater than 10% cost increase, blue text a greater than 10% cost reduction: Text in italics denotes the overall size of the respiratory drug market in that country.
Abbreviations: X, no equivalent DPI; o, no MDI to replace; N/A, no drugs in class in inhaler on market.